{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T11:52:04Z","timestamp":1789645924193,"version":"4.0.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,12]],"date-time":"2024-11-12T00:00:00Z","timestamp":1731369600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000927","name":"Prostate Cancer Foundation of Australia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000927","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004224","name":"Peter MacCallum Cancer Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004224","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008719","name":"Movember Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008719","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","euoncology.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Oncology"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.euo.2024.11.006","type":"journal-article","created":{"date-parts":[[2024,11,29]],"date-time":"2024-11-29T00:12:18Z","timestamp":1732839138000},"page":"422-429","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Baseline Nodal Status on 68Ga-PSMA-11 Positron Emission Tomography\/Computed Tomography in Men with Intermediate- to High-risk Prostate Cancer Is Prognostic for Treatment Failure: Follow-up of the proPSMA Trial"],"prefix":"10.1016","volume":"9","author":[{"given":"Michael S.","family":"Hofman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veeru","family":"Kasivisvanathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Link","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Buteau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew J.","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roslyn J.","family":"Francis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Vela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Rutherford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jarad M.","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Frydenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramdave","family":"Shakher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lih-Ming","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"Taubman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sze","family":"Ting Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Hsiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Roach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Nottage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Kirkwood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dickon","family":"Hayne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir","family":"Iravani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"O\u2019Brien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan","family":"Lawrentschuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Declan G.","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euo.2024.11.006_b0005","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/S0140-6736(20)30314-7","article-title":"Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study","volume":"395","author":"Hofman","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.euo.2024.11.006_b0010","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.eururo.2023.03.001","volume":"84","author":"Chow","year":"2023","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2024.11.006_b0015","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.eururo.2020.11.043","article-title":"Is prostate-specific membrane antigen positron emission tomography\/computed tomography imaging cost-effective in prostate cancer: an analysis informed by the proPSMA trial","volume":"79","author":"de Feria Cardet","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2024.11.006_b0020","unstructured":"EAU. EAU guidelines. Presented at the EAU Annual Congress Paris; April 2024."},{"key":"10.1016\/j.euo.2024.11.006_b0025","unstructured":"Mottet N, Cornford P, van den Bergh RCN, et al. EAU - EANM - ESTRO - ESUR - SIOG 2022 guidelines on prostate cancer 2022. https:\/\/uroweb.org\/guidelines\/prostate-cancer."},{"key":"10.1016\/j.euo.2024.11.006_b0030","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1200\/JCO.18.01927","article-title":"Strategies for evaluation of novel imaging in prostate cancer: putting the horse back before the cart","volume":"37","author":"Vapiwala","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2024.11.006_b0035","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.eururo.2022.11.002","article-title":"Management of patients with advanced prostate cancer. Part I: intermediate-\/high-risk and locally advanced disease, biochemical relapse, and side effects of hormonal treatment: report of the Advanced Prostate Cancer Consensus Conference 2022","volume":"83","author":"Gillessen","year":"2023","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2024.11.006_b0040","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.ejca.2023.02.018","article-title":"Management of patients with advanced prostate cancer\u2014metastatic and\/or castration-resistant prostate cancer: report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022","volume":"185","author":"Gillessen","year":"2023","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.euo.2024.11.006_b0045","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1016\/S0140-6736(24)00651-2","article-title":"The Lancet Commission on prostate cancer: planning for the surge in cases","volume":"403","author":"James","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.euo.2024.11.006_b0050","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1111\/bju.14374","article-title":"A prospective randomized multicentre study of the impact of gallium-68 prostate-specific membrane antigen (PSMA) PET\/CT imaging for staging high-risk prostate cancer prior to curative-intent surgery or radiotherapy (proPSMA study): clinical trial protocol","volume":"122","author":"Hofman","year":"2018","journal-title":"BJU Int"},{"key":"10.1016\/j.euo.2024.11.006_b0055","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1111\/bju.15881","article-title":"The prognostic value of lymph node staging with prostate-specific membrane antigen (PSMA) positron emission tomography\/computed tomography (PET\/CT) and extended pelvic lymph node dissection in node-positive patients with prostate cancer","volume":"131","author":"Meijer","year":"2023","journal-title":"BJU Int"},{"key":"10.1016\/j.euo.2024.11.006_b0060","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1097\/JU.0000000000001596","volume":"205","author":"Amiel","year":"2021","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2024.11.006_b0065","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1016\/S1470-2045(24)00326-7","article-title":"Combining PSMA-PET and PROMISE to re-define disease stage and risk in patients with prostate cancer: a multicentre retrospective study","volume":"25","author":"Karpinski","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euo.2024.11.006_b0070","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1002\/pros.24627","article-title":"The diagnostic accuracy of Ga-PSMA-PET\/CT in primary staging of patients with high-risk nonmetastatic prostate cancer treated with radical prostatectomy: a single-center cohort analysis","volume":"84","author":"Rajwa","year":"2024","journal-title":"Prostate"},{"key":"10.1016\/j.euo.2024.11.006_b0075","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.38550","article-title":"Performance of a prostate-specific membrane antigen positron emission tomography\/computed tomography\u2013derived risk-stratification tool for high-risk and very high-risk prostate cancer","volume":"4","author":"Xiang","year":"2021","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.euo.2024.11.006_b0080","doi-asserted-by":"crossref","first-page":"7.e1","DOI":"10.1016\/j.urolonc.2021.06.008","article-title":"PSMA PET predicts metastasis-free survival in the setting of salvage radiotherapy after radical prostatectomy","volume":"40","author":"Wenzel","year":"2022","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euo.2024.11.006_b0085","doi-asserted-by":"crossref","first-page":"866","DOI":"10.2967\/jnumed.119.235028","article-title":"3-Year freedom from progression after 68Ga-PSMA PET\/CT\u2013triaged management in men with biochemical recurrence after radical prostatectomy: results of a prospective multicenter trial","volume":"61","author":"Emmett","year":"2020","journal-title":"J Nucl Med"},{"key":"10.1016\/j.euo.2024.11.006_b0090","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/s41585-022-00670-6","article-title":"Using PSMA imaging for prognostication in localized and advanced prostate cancer","volume":"20","author":"Roberts","year":"2023","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.euo.2024.11.006_b0095","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.eururo.2022.10.005","article-title":"More accurate imaging is not stage migration: time to move from \u201cHubble\u201d to \u201cWebb\u201d in hormone-sensitive prostate cancer","volume":"83","author":"Ayati","year":"2023","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2024.11.006_b0100","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1186\/s12885-020-07192-7","article-title":"Clinical impact of PSMA PET\/CT in primary prostate cancer compared to conventional nodal and distant staging: a retrospective single center study","volume":"20","author":"Donswijk","year":"2020","journal-title":"BMC Cancer"},{"key":"10.1016\/j.euo.2024.11.006_b0105","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1056\/NEJMoa1903835","article-title":"Enzalutamide with standard first-line therapy in metastatic prostate cancer","volume":"381","author":"Davis","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2024.11.006_b0110","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/S0140-6736(22)00367-1","article-title":"Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 \u00d7 2 factorial design","volume":"399","author":"Fizazi","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.euo.2024.11.006_b0115","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.eururo.2023.02.002","article-title":"Second version of the prostate cancer molecular imaging standardized evaluation framework including response evaluation for clinical trials (PROMISE V2)","volume":"83","author":"Seifert","year":"2023","journal-title":"Eur Urol"}],"container-title":["European Urology Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931124002517?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931124002517?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T02:36:44Z","timestamp":1778899004000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2588931124002517"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":23,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S2588931124002517"],"URL":"https:\/\/doi.org\/10.1016\/j.euo.2024.11.006","relation":{},"ISSN":["2588-9311"],"issn-type":[{"value":"2588-9311","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Baseline Nodal Status on 68Ga-PSMA-11 Positron Emission Tomography\/Computed Tomography in Men with Intermediate- to High-risk Prostate Cancer Is Prognostic for Treatment Failure: Follow-up of the proPSMA Trial","name":"articletitle","label":"Article Title"},{"value":"European Urology Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euo.2024.11.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}